文献速递甲状腺疾病

远处转移性和去分化甲状腺癌中全球DNA低甲基化增加

Increased Global DNA Hypomethylation in Distant Metastatic and Dedifferentiated Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

本研究以Alu重复序列低甲基化作为全球DNA低甲基化的替代标志物,检测了90例原发性甲状腺肿瘤、24例远处转移灶和20例正常甲状腺组织。远处转移性分化型甲状腺癌和低分化/未分化甲状腺癌的低甲基化程度高于正常甲状腺组织,而低危和儿童分化型甲状腺癌未受影响;校正甲状腺癌风险分类后,低甲基化与死亡风险的关联消失。

要点

  • 远处转移性分化型甲状腺癌和低分化/未分化甲状腺癌中Alu低甲基化程度高于正常甲状腺组织。
  • 低危和儿童分化型甲状腺癌未受低甲基化影响。
  • 校正甲状腺癌风险分类后,肿瘤低甲基化与甲状腺癌相关死亡和全因死亡的关联消失。

核心结论

  • 远处转移性分化型甲状腺癌、低分化甲状腺癌和未分化甲状腺癌 increasingly 受全球Alu低甲基化影响,提示该表观遗传学改变可能参与甲状腺癌进展和去分化。

研究设计与样本

  • 研究纳入90例原发性甲状腺肿瘤(28例低危分化型甲状腺癌、13例儿童分化型甲状腺癌、33例远处转移性分化型甲状腺癌、7例低分化甲状腺癌和9例未分化甲状腺癌)、24例远处转移灶和20例正常甲状腺组织。
  • 采用Quantification of Unmethylated Alu技术评估Alu重复序列全球低甲基化,通过Sanger测序确定BRAF和RAS突变。

主要发现

  • 远处转移性分化型甲状腺癌Alu低甲基化中位数为4.0(四分位距3.1至6.2),低分化/未分化甲状腺癌中位数为9.3(四分位距7.0至12.1),正常甲状腺组织中位数为2.75(四分位距2.30至3.15)。
  • 低危和儿童分化型甲状腺癌未受低甲基化影响。
  • 远处转移灶与配对原发肿瘤的Alu低甲基化程度相似。
  • 在远处转移性分化型甲状腺癌中,BRAF突变肿瘤的Alu低甲基化程度高于RAS突变肿瘤。
  • Kaplan-Meier和Cox回归分析显示甲状腺癌相关死亡和全因死亡与肿瘤低甲基化相关,但校正甲状腺癌风险分类后该关联消失。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Global DNA hypomethylation is a major event for the development and progression of cancer, although the significance in thyroid cancer remains unclear. Therefore, we aimed to investigate its role in thyroid cancer progression and its potential as a prognostic marker. METHODS: Global hypomethylation of Alu repeats was used as a surrogate marker for DNA global hypomethylation, and was assessed using the Quantification of Unmethylated Alu technique. Mutations in BRAF and RAS were determined by Sanger sequencing. RESULTS: Ninety primary thyroid tumors were included [28 low-risk differentiated thyroid cancer (DTC), 13 pediatric DTC, 33 distant metastatic DTC, 7 poorly differentiated thyroid cancer (PDTC), and 9 anaplastic thyroid cancer (ATC)], as well as 24 distant metastases and 20 normal thyroid tissues. An increasing hypomethylation was found for distant metastatic DTC [median, 4.0; interquartile range (IQR), 3.1 to 6.2] and PDTC/ATC (median, 9.3; IQR, 7.0 to 12.1) as compared with normal thyroid tissue (median, 2.75; IQR, 2.30 to 3.15), whereas low-risk and pediatric DTC were not affected by hypomethylation. Alu hypomethylation was similar between distant metastases and matched primary tumors. Within distant metastatic DTC, Alu hypomethylation was increased in BRAF vs RAS mutated tumors. Kaplan-Meier and Cox regression analyses showed that thyroid cancer-related and all-cause mortality were associated with tumor hypomethylation, but this association was lost after adjustment for thyroid cancer risk category. CONCLUSION: Distant metastatic DTC, PDTC, and ATC were increasingly affected by global Alu hypomethylation, suggesting that this epigenetic entity may be involved in thyroid cancer progression and dedifferentiation.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Klein Hesselink EN, Zafon C, Villalmanzo N, et al. Increased Global DNA Hypomethylation in Distant Metastatic and Dedifferentiated Thyroid Cancer. J Clin Endocrinol Metab. 2018. PMID: 29165662. doi:10.1210/jc.2017-01613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。